BioMarin prices Vimizim at $1,068 per vial; $380k expected annual cost
This article was originally published in Scrip
Executive Summary
Patients with a rare lysosomal storage disorder, known as Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A syndrome, will be paying $380,000 per year for BioMarin Pharmaceutical's newly approved enzyme replacement treatment (ERT) Vimizim (elosulfase alfa), company officials revealed on 18 February.